Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich [alpha]2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma L...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-06, Vol.18 (6), p.e0286415 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | e0286415 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Ichimiya, Tadashi Kazama, Tomoe Ishigami, Keisuke Yokoyama, Yoshihiro Hayashi, Yuki Takahashi, Satoshi Itoi, Takao Nakase, Hiroshi |
| description | Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich [alpha]2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma LRG can be used as an alternative to serum LRG. Therefore, in this retrospective study, we evaluated the usefulness of plasma LRG compared to serum LRG. We conducted a single-center retrospective observational study. A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn's disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled. Serum and plasma LRG levels were measured using the NANOPIA LRG kit. Disease activity was assessed using the Crohn's Disease Activity Index (CDAI) for CD and partial Mayo (pMayo) score for UC. Endoscopic activity was evaluated using the Mayo Endoscopic Subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with UC and the Simple Endoscopic Score for Crohn's Disease (SES-CD) score in patients with CD. Serum LRG levels significantly correlated with plasma LRG levels (r = 0.990, p |
| doi_str_mv | 10.1371/journal.pone.0286415 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A754385935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A754385935</galeid><sourcerecordid>A754385935</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1665-534fbadf7fd5211a308580b014814fd47bc6b792b992c130787b06caf199e18c3</originalsourceid><addsrcrecordid>eNqNkU1r3DAQhk1poNuk_6AHQSHQgzeSZfnjuIR8LAQW0iSXUJaxPPJqK1tGktvsP8jPjpbmsAs9lDnMMDzvyzBvknxldM54yS62dnIDmPloB5zTrCpyJj4kM1bzLC0yyj8ezJ-Sz95vKRW8KopZ8roYR6MlBG0HYhUZDfgeCJiA0TLo30iCJR7d1BNlHekR_OT00BGDk9QDpk7LDXkGM27gZ5Z2Zift6GxAPRDwBEijbQ_uF7q9vR6Ugb6HYN2ONPYPGtJqHz3xLDlRYDx-ee-nyeP11cPlbXq3ulleLu7SjhWFSAXPVQOtKlUrMsaA00pUtKEsr1iu2rxsZNGUddbUdSYZp2VVNrSQoFhdI6skP02-_fXtwOA63mODA9lrL9eLUuS8EjUXkZr_g4rVYq9lfLPScX8k-H4kiEzAl9DB5P16-eP-_9nV0zF7fsBuMAaz8dZM-7z8IfgGAoehLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ichimiya, Tadashi ; Kazama, Tomoe ; Ishigami, Keisuke ; Yokoyama, Yoshihiro ; Hayashi, Yuki ; Takahashi, Satoshi ; Itoi, Takao ; Nakase, Hiroshi</creator><creatorcontrib>Ichimiya, Tadashi ; Kazama, Tomoe ; Ishigami, Keisuke ; Yokoyama, Yoshihiro ; Hayashi, Yuki ; Takahashi, Satoshi ; Itoi, Takao ; Nakase, Hiroshi</creatorcontrib><description>Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich [alpha]2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma LRG can be used as an alternative to serum LRG. Therefore, in this retrospective study, we evaluated the usefulness of plasma LRG compared to serum LRG. We conducted a single-center retrospective observational study. A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn's disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled. Serum and plasma LRG levels were measured using the NANOPIA LRG kit. Disease activity was assessed using the Crohn's Disease Activity Index (CDAI) for CD and partial Mayo (pMayo) score for UC. Endoscopic activity was evaluated using the Mayo Endoscopic Subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with UC and the Simple Endoscopic Score for Crohn's Disease (SES-CD) score in patients with CD. Serum LRG levels significantly correlated with plasma LRG levels (r = 0.990, p<0.0001). Plasma LRG levels were significantly associated with SES-CD (r = 0.992, p<0.0001), indicating that plasma LRG levels may predict endoscopic activity in CD. In UC patients, the cutoff values of plasma LRG for remission were 12.7 [mu]g/mL for MES [less than or equal to]1 and 10.0 [mu]g/mL for UCEIS of = 0. The present study showed that plasma LRG levels correlate well with serum LRG levels. Therefore, plasma LRG can be clinically applied as a biomarker for assessing endoscopic disease activity in patients with IBD.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0286415</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Biological markers ; Blood plasma ; Comparative analysis ; Diagnosis ; Glycoproteins ; Health aspects ; Inflammatory bowel diseases ; Measurement ; Medical colleges ; Medical research ; Medicine, Experimental ; Ulcerative colitis</subject><ispartof>PloS one, 2023-06, Vol.18 (6), p.e0286415</ispartof><rights>COPYRIGHT 2023 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids></links><search><creatorcontrib>Ichimiya, Tadashi</creatorcontrib><creatorcontrib>Kazama, Tomoe</creatorcontrib><creatorcontrib>Ishigami, Keisuke</creatorcontrib><creatorcontrib>Yokoyama, Yoshihiro</creatorcontrib><creatorcontrib>Hayashi, Yuki</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><creatorcontrib>Itoi, Takao</creatorcontrib><creatorcontrib>Nakase, Hiroshi</creatorcontrib><title>Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease</title><title>PloS one</title><description>Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich [alpha]2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma LRG can be used as an alternative to serum LRG. Therefore, in this retrospective study, we evaluated the usefulness of plasma LRG compared to serum LRG. We conducted a single-center retrospective observational study. A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn's disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled. Serum and plasma LRG levels were measured using the NANOPIA LRG kit. Disease activity was assessed using the Crohn's Disease Activity Index (CDAI) for CD and partial Mayo (pMayo) score for UC. Endoscopic activity was evaluated using the Mayo Endoscopic Subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with UC and the Simple Endoscopic Score for Crohn's Disease (SES-CD) score in patients with CD. Serum LRG levels significantly correlated with plasma LRG levels (r = 0.990, p<0.0001). Plasma LRG levels were significantly associated with SES-CD (r = 0.992, p<0.0001), indicating that plasma LRG levels may predict endoscopic activity in CD. In UC patients, the cutoff values of plasma LRG for remission were 12.7 [mu]g/mL for MES [less than or equal to]1 and 10.0 [mu]g/mL for UCEIS of = 0. The present study showed that plasma LRG levels correlate well with serum LRG levels. Therefore, plasma LRG can be clinically applied as a biomarker for assessing endoscopic disease activity in patients with IBD.</description><subject>Biological markers</subject><subject>Blood plasma</subject><subject>Comparative analysis</subject><subject>Diagnosis</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Inflammatory bowel diseases</subject><subject>Measurement</subject><subject>Medical colleges</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Ulcerative colitis</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkU1r3DAQhk1poNuk_6AHQSHQgzeSZfnjuIR8LAQW0iSXUJaxPPJqK1tGktvsP8jPjpbmsAs9lDnMMDzvyzBvknxldM54yS62dnIDmPloB5zTrCpyJj4kM1bzLC0yyj8ezJ-Sz95vKRW8KopZ8roYR6MlBG0HYhUZDfgeCJiA0TLo30iCJR7d1BNlHekR_OT00BGDk9QDpk7LDXkGM27gZ5Z2Zift6GxAPRDwBEijbQ_uF7q9vR6Ugb6HYN2ONPYPGtJqHz3xLDlRYDx-ee-nyeP11cPlbXq3ulleLu7SjhWFSAXPVQOtKlUrMsaA00pUtKEsr1iu2rxsZNGUddbUdSYZp2VVNrSQoFhdI6skP02-_fXtwOA63mODA9lrL9eLUuS8EjUXkZr_g4rVYq9lfLPScX8k-H4kiEzAl9DB5P16-eP-_9nV0zF7fsBuMAaz8dZM-7z8IfgGAoehLA</recordid><startdate>20230623</startdate><enddate>20230623</enddate><creator>Ichimiya, Tadashi</creator><creator>Kazama, Tomoe</creator><creator>Ishigami, Keisuke</creator><creator>Yokoyama, Yoshihiro</creator><creator>Hayashi, Yuki</creator><creator>Takahashi, Satoshi</creator><creator>Itoi, Takao</creator><creator>Nakase, Hiroshi</creator><general>Public Library of Science</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20230623</creationdate><title>Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease</title><author>Ichimiya, Tadashi ; Kazama, Tomoe ; Ishigami, Keisuke ; Yokoyama, Yoshihiro ; Hayashi, Yuki ; Takahashi, Satoshi ; Itoi, Takao ; Nakase, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1665-534fbadf7fd5211a308580b014814fd47bc6b792b992c130787b06caf199e18c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biological markers</topic><topic>Blood plasma</topic><topic>Comparative analysis</topic><topic>Diagnosis</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Inflammatory bowel diseases</topic><topic>Measurement</topic><topic>Medical colleges</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ichimiya, Tadashi</creatorcontrib><creatorcontrib>Kazama, Tomoe</creatorcontrib><creatorcontrib>Ishigami, Keisuke</creatorcontrib><creatorcontrib>Yokoyama, Yoshihiro</creatorcontrib><creatorcontrib>Hayashi, Yuki</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><creatorcontrib>Itoi, Takao</creatorcontrib><creatorcontrib>Nakase, Hiroshi</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ichimiya, Tadashi</au><au>Kazama, Tomoe</au><au>Ishigami, Keisuke</au><au>Yokoyama, Yoshihiro</au><au>Hayashi, Yuki</au><au>Takahashi, Satoshi</au><au>Itoi, Takao</au><au>Nakase, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease</atitle><jtitle>PloS one</jtitle><date>2023-06-23</date><risdate>2023</risdate><volume>18</volume><issue>6</issue><spage>e0286415</spage><pages>e0286415-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich [alpha]2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma LRG can be used as an alternative to serum LRG. Therefore, in this retrospective study, we evaluated the usefulness of plasma LRG compared to serum LRG. We conducted a single-center retrospective observational study. A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn's disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled. Serum and plasma LRG levels were measured using the NANOPIA LRG kit. Disease activity was assessed using the Crohn's Disease Activity Index (CDAI) for CD and partial Mayo (pMayo) score for UC. Endoscopic activity was evaluated using the Mayo Endoscopic Subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with UC and the Simple Endoscopic Score for Crohn's Disease (SES-CD) score in patients with CD. Serum LRG levels significantly correlated with plasma LRG levels (r = 0.990, p<0.0001). Plasma LRG levels were significantly associated with SES-CD (r = 0.992, p<0.0001), indicating that plasma LRG levels may predict endoscopic activity in CD. In UC patients, the cutoff values of plasma LRG for remission were 12.7 [mu]g/mL for MES [less than or equal to]1 and 10.0 [mu]g/mL for UCEIS of = 0. The present study showed that plasma LRG levels correlate well with serum LRG levels. Therefore, plasma LRG can be clinically applied as a biomarker for assessing endoscopic disease activity in patients with IBD.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0286415</doi><tpages>e0286415</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-06, Vol.18 (6), p.e0286415 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A754385935 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biological markers Blood plasma Comparative analysis Diagnosis Glycoproteins Health aspects Inflammatory bowel diseases Measurement Medical colleges Medical research Medicine, Experimental Ulcerative colitis |
| title | Application of plasma alternative to serum for measuring leucine-rich [alpha]2-glycoprotein as a biomarker of inflammatory bowel disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A22%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20plasma%20alternative%20to%20serum%20for%20measuring%20leucine-rich%20%5Balpha%5D2-glycoprotein%20as%20a%20biomarker%20of%20inflammatory%20bowel%20disease&rft.jtitle=PloS%20one&rft.au=Ichimiya,%20Tadashi&rft.date=2023-06-23&rft.volume=18&rft.issue=6&rft.spage=e0286415&rft.pages=e0286415-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0286415&rft_dat=%3Cgale%3EA754385935%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A754385935&rfr_iscdi=true |